The following is a synopsis of several recent COVID-19 research. They contain research that requires more investigation to confirm the findings and has not yet been verified by peer review.
The response of chemo patients to vaccination improves with boosters.
New research quantifies the enhanced COVID-19 protection achieved with a third booster dose of the vaccine from Pfizer Inc and BioNTech SE in cancer patients undergoing chemotherapy.
The Booster Vaccine Shot Won’t Affect The Cancer Patients Immune System
Chemotherapy can impair cancer patients’ capacity to fight infections and respond correctly to vaccinations, said Deepta Bhattacharya of the University of Arizona College of Medicine, coauthor of the Nature Medicine research.
Her team looked at 53 patients who were undergoing chemotherapy for solid-tumor malignancies and were given two doses of the vaccine. After immunization, almost all of the individuals developed an immunological response.
However, “in nearly every parameter that we evaluated, the amplitude of these reactions was worse than in those without cancer,” Bhattacharya added. This makes cancer patients more vulnerable to infection and COVID-19 than healthy vaccinated persons. The researchers were able to return 20 of the trial participants for a third vaccination dosage in order to evaluate if immune responses improved.
Tiny Italian research shows that lingering depression in COVID-19 survivors may be very curable. Doctors employed a commonly used type of antidepressant medication known as selective serotonin reuptake inhibitors, or SSRIs, to treat 58 patients who had developed post-COVID depression.
These include sertraline, marketed by Pfizer under the trade name Zoloft, Paxil (paroxetine) by GlaxoSmithKline, Prozac (fluoxetine) by Eli Lilly and Company, and Celexa (citalopram) by AbbVie’s Allergan business. SSRIs typically help around 66 percent of patients, but among individuals with post-COVID-19 depression, 91 percent reacted to therapy after four weeks, according to a study presented this week at the European College of Neuropsychopharmacology.
They hypothesize that depression following COVID-19 is induced by coronavirus inflammation, and they remark that SSRIs have some anti-inflammatory and antiviral effects. Separate research presented at the symposium discovered that while SSRIs reduced sadness in COVID-19 survivors, they had no influence on their anxiety levels.
Vaccinated people should continue to wear masks in public because they can carry – and perhaps shed – as many viruses as unvaccinated people without realizing it, according to new research. The researchers looked at viral levels at the time of diagnosis in 869 individuals, including 632 who were asymptomatic.
The majority of the illnesses were caused by the coronavirus’s extremely infectious Delta form. According to a paper uploaded on medRxiv on Tuesday ahead of peer review, they observed no statistically significant variations in average virus loads between vaccinated and unvaccinated people, or between those with or without symptoms, or across various age groups, genders, or vaccination types.
Our work does not give information on infectiousness, according to Richard Michelmore of the University of California, Davis, who points out that virus transmission is impacted by a variety of factors other than vaccination status and viral load. It’s not safe to believe that just because you’ve been vaccinated means you can’t become sick or infect others, even if you’re asymptomatic, he says.
COVID-19 vaccinations lower the likelihood of infection and the severity of illness. People who have been vaccinated against COVID-19 should still wear masks in public since they may infect others if they get infected, according to the researchers.